CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $67,000 | -65.5% | 600 | -50.0% | 0.00% | – |
| Q2 2021 | $194,000 | +32.9% | 1,200 | 0.0% | 0.00% | – |
| Q1 2021 | $146,000 | -85.6% | 1,200 | 0.0% | 0.00% | – |
| Q4 2020 | $1,011,000 | +405.5% | 1,200 | -50.0% | 0.00% | -100.0% |
| Q3 2020 | $200,000 | +13.6% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $176,000 | +245.1% | 2,400 | +100.0% | 0.00% | – |
| Q1 2020 | $51,000 | -30.1% | 1,200 | 0.0% | 0.00% | – |
| Q4 2019 | $73,000 | +942.9% | 1,200 | +627.3% | 0.00% | – |
| Q3 2019 | $7,000 | -87.7% | 165 | -86.2% | 0.00% | – |
| Q2 2019 | $57,000 | +32.6% | 1,200 | 0.0% | 0.00% | – |
| Q1 2019 | $43,000 | +26.5% | 1,200 | 0.0% | 0.00% | – |
| Q4 2018 | $34,000 | -35.8% | 1,200 | 0.0% | 0.00% | – |
| Q3 2018 | $53,000 | -25.4% | 1,200 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $71,000 | -9.0% | 1,200 | -29.4% | 0.00% | 0.0% |
| Q1 2018 | $78,000 | +387.5% | 1,700 | +142.9% | 0.00% | – |
| Q4 2017 | $16,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |